All Stories

  1. Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial

    Article • BMJ Open, January 2020, BMJ

    Dr Nina Kimer, Clinical Chair Professor Henning Gronbaek

  2. Prognosis of patients with ascites after PleurX insertion: an observational study

    Article • Scandinavian Journal of Gastroenterology, February 2018, Taylor & Francis

    Dr Nina Kimer

  3. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial

    Article • Journal of Gastroenterology and Hepatology, December 2017, Wiley

    Dr Nina Kimer, Søren Sørensen

  4. The royal free hospital cirrhosis glomerular filtration rate: Validation in a danish cohort

    Article • Hepatology, August 2017, Wiley

    Dr Nina Kimer

  5. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double‐blind, placebo‐controlled trial

    Article • Hepatology, December 2016, Wiley

    Dr Nina Kimer

  6. Beta-blockers alone or with isosorbide mononitrate for primary prevention in adults with cirrhosis and gastro-oesophageal varices

    Article • Cochrane Database of Systematic Reviews, May 2015, Wiley

    Dr Nina Kimer

  7. Rifaximin for people with hepatic encephalopathy

    Article • Cochrane Database of Systematic Reviews, March 2015, Wiley

    Dr Nina Kimer

  8. Letter: the effects of rifaximin in hepatic encephalopathy - authors' reply

    Article • Alimentary Pharmacology & Therapeutics, September 2014, Wiley

    Dr Nina Kimer

  9. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature

    Article • Scandinavian Journal of Gastroenterology, August 2014, Taylor & Francis

    Dr Nina Kimer

  10. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy

    Article • Alimentary Pharmacology & Therapeutics, May 2014, Wiley

    Dr Nina Kimer

  11. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy

    Article • Patient Preference and Adherence, March 2014, Taylor & Francis

    Dr Nina Kimer

  12. New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state

    Article • European Journal of Clinical Investigation, February 2014, Wiley

    Dr Nina Kimer

  13. 206 RIFAXIMIN IN THE TREATMENT AND PROPHYLAXIS OF HEPATIC ENCEPHALOPATHY IN CHRONIC LIVER DISEASE: A META-ANALYSIS

    Article • Journal of Hepatology, April 2013, Elsevier

    Dr Nina Kimer

  14. 584 NEW VASCULAR BIOMARKERS IN CIRRHOSIS: ORGAN EXTRACTION AND RELATION TO THE VASODILATORY STATE

    Article • Journal of Hepatology, April 2013, Elsevier

    Dr Nina Kimer

  15. The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy

    Article • Metabolic Brain Disease, January 2013, Springer Science + Business Media

    Dr Nina Kimer

  16. Letter: vaptans for the treatment of hyponatraemia and ascites in patients with cirrhosis - authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, November 2012, Wiley

    Dr Nina Kimer

  17. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia

    Article • Alimentary Pharmacology & Therapeutics, August 2012, Wiley

    Dr Nina Kimer

  18. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials

    Article • BMJ Open, January 2012, BMJ

    Dr Nina Kimer

  19. Cameron lesions: an often overlooked cause of iron deficiency anaemia in patients with large hiatal hernias

    Article • BMJ Case Reports, October 2010, BMJ

    Dr Nina Kimer